Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
21 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05132075 | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer(KontRASt-02) | active not recruiting | Phase 3 | 95 | Novartis PharmaceuticalsINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | Phase 3 | 6,430 | Mats HeymanOTHER | 15 | Aug 12, 2026 |
| clinicaltrials |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer(OlympiA) | active not recruiting | Phase 3 | 1,837 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT05223647 | Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer(TRIPLEX) | terminated | Phase 3 | 239 | Norwegian University of Science and TechnologyOTHER | 5 | Jan 28, 2026 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients(BRAVO) | terminated | Phase 3 | 216 | Tesaro, Inc.INDUSTRY | 14 | Nov 15, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT01322490 | A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer(Prospect) | completed | Phase 3 | 1,297 | Bavarian NordicINDUSTRY | 16 | Sep 4, 2019 | clinicaltrials |
| NCT01305655 | Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL(NOPHOCPG2) | completed | Phase 3 | 47 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Sep 28, 2018 | clinicaltrials |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer(NordICC) | active not recruiting | Phase 3 | 95,000 | Oslo University HospitalOTHER | 6 | Jun 19, 2017 | clinicaltrials |
| NCT00816049 | ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy(ALL2008con) | completed | Phase 3 | 775 | Rigshospitalet, DenmarkOTHER | 5 | Apr 21, 2017 | clinicaltrials |
| NCT00819351 | ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase | completed | Phase 3 | 650 | Rigshospitalet, DenmarkOTHER | 5 | Apr 21, 2017 | clinicaltrials |
| NCT01828489 | Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years(AML2012) | unknown | Phase 3 | 300 | Vastra Gotaland RegionOTHER_GOV | 9 | Jan 10, 2017 | clinicaltrials |
| NCT01369329 | A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) | completed | Phase 3 | 769 | Janssen Research & Development, LLCINDUSTRY | 23 | Dec 7, 2016 | clinicaltrials |
| NCT00720798 | An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies | completed | Phase 3 | 2,067 | Hoffmann-La RocheINDUSTRY | 34 | Sep 30, 2014 | clinicaltrials |
| NCT00376792 | Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | unknown | Phase 3 | 396 | Scandinavian Prostate Cancer GroupNETWORK | 5 | Aug 26, 2013 | clinicaltrials |
| NCT00991744 | Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) | suspended | Phase 3 | 100 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Oct 10, 2012 | clinicaltrials |
| NCT00256698 | Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy(FACT) | completed | Phase 3 | 514 | AstraZenecaINDUSTRY | 12 | Aug 1, 2012 | clinicaltrials |
| NCT00417911 | Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients | completed | Phase 3 | 400 | Nordic Myeloma Study GroupOTHER | 5 | Jun 22, 2010 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials